BioMark study reports 24-feature liquid biopsy model posts 96.9% ROC-AUC in lung cancer detection

• BioMark Diagnostics highlighted two new peer-reviewed studies published on Aug. 17–18, 2026, extending a run of five papers in nine months.
• Results have already been presented through journal publication, not flagged for a future conference readout.
• Research supports the company’s blood-based lung cancer screening approach, showing strong case-control separation in large patient cohorts.
• Work also points to lower-cost testing through smaller diagnostic panels, while reducing smoking-related bias that can distort real-world performance.
• BioMark framed the publications as de-risking its path toward external validation trials and regulatory submissions in North America.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMark Diagnostics Inc. published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.